AbbVie ABBV and AstraZeneca AZN are both global healthcare companies with diversified drug portfolios. Both companies have strong leadership positions in immunology and oncology areas. While AbbVie ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, ...

Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let us unpack what the current price really implies about its long term ...

Erica Andersen and Christopher Sipes, co-chairs of Covington’s patent litigation group, and co-counsel David Frazier, the global vice chair of Latham’s intellectual property litigation practice, ...

Offers a broad portfolio of branded pharmaceuticals, including HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, and BOTOX, targeting immunology, oncology, neuroscience, and eye care markets. Generates ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

AbbVie is also developing oncology therapies beyond ADC. A key candidate in the company’s pipeline is etentamig/ABBV-383, a ...